Loading...
Market
What will Remi Barbier do next by September 30, 2025?
3
Resolution / Starting Odds
Remi Barbier joins another biotech company • 25%
Remi Barbier retires • 25%
Remi Barbier starts a new company • 25%
Remi Barbier takes a non-executive role • 25%
Publicly available information such as LinkedIn profiles, company announcements, and news reports
Story
Cassava Sciences and CEO Remi Barbier Charged by SEC Over Alzheimer's Drug Simufilam, Settle for $40 Million
Sep 26, 2024, 11:57 PM
Cassava Sciences and two former executives, including founder and CEO Remi Barbier and his wife, Lindsay Burns, have been charged by the U.S. Securities and Exchange Commission (SEC) for making misleading claims about the results of clinical trials for their Alzheimer's drug, simufilam. The company and the executives have agreed to pay over $40 million to settle the charges announced on Thursday. The SEC alleges that Cassava Sciences falsified Phase 2 trial data, with manipulated research results that showed no measurable cognitive improvement in patients' episodic memory. A Cassava-affiliated university scientist, Dr. Wang from CUNY, was also charged for manipulating clinical trial results.
View original story
Similar markets
Retires from politics • 25%
Continues political career • 25%
Takes a break • 25%
Joins private sector • 25%
Anne Hidalgo • 25%
Raphaël Glucksmann • 25%
Other prominent figure • 25%
No major endorsement • 25%
Return to private practice • 25%
Run for public office • 25%
Join a think tank or academic position • 25%
Remain in a government role • 25%
Venture capital firm • 25%
Private equity firm • 25%
Corporate investor • 25%
Other • 25%
Founders step down • 25%
Founders remain in charge • 25%
Founders face legal consequences • 25%
Other outcomes • 25%
Current CEO remains • 25%
New CEO appointed • 25%
Interim CEO in place • 25%
Other • 25%
Critical of X • 25%
Supportive of X • 25%
Neutral • 25%
No statement • 25%
Andreessen Horowitz • 25%
SoftBank • 25%
Tiger Global • 25%
Other • 25%